[{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ AstraZeneca"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Silence and AstraZeneca will collaborate to use Silence’s mRNAi GOLD platform to develop siRNA therapeutics for various diseases, including cardiovascular and respiratory.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $80.0 million

                          February 23, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : AstraZeneca

                          Deal Size : $570.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.

                          Product Name : SLN360

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          February 17, 2021

                          Lead Product(s) : Zerlasiran

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Medpace, Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Results presented show that the distribution of SLN360 is confined to the liver (target organ) and kidney (route of elimination) as intended, with levels of SLN360 in other organs (including reproductive organs) less than 1% of peak liver levels.

                          Product Name : SLN360

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          November 16, 2020

                          Lead Product(s) : Zerlasiran

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : $60.0 million

                          March 25, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : AstraZeneca

                          Deal Size : $2,080.0 million

                          Deal Type : Collaboration

                          blank